SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia

Sodium–glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal E...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez-Fernandez, Beatriz, Sarafidis, Pantelis, Kanbay, Mehmet, Navarro-González, Juan F, Soler, María José, Górriz, Jose Luis, Ortiz, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Editorial Comments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577767/
https://www.ncbi.nlm.nih.gov/pubmed/33123352
http://dx.doi.org/10.1093/ckj/sfaa198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577767/
https://www.ncbi.nlm.nih.gov/pubmed/33123352
http://dx.doi.org/10.1093/ckj/sfaa198

Ejemplares similares